Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Anesthesiology Reports
Erschienen in:

13.10.2022 | Blood Management (KA Tanaka, Section Editor)

Antifibrinolytics in Cardiac Surgery: What Is the Best Practice in 2022?

verfasst von: Erik R. Strauss, Monica Taneja, Richard Booth, Susan Sankova, Megan G. Anders

Erschienen in: Current Anesthesiology Reports | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review describes the latest information related to the administration of lysine analogues during cardiac surgery. An awareness of appropriate antifibrinolytic administration will maximize benefit for blood conservation efforts and possibly decrease morbidity and mortality.

Recent Findings

Recent pharmacodynamic assessments for antifibrinolytics are more sensitive. Research suggests that lower dose regimens may not provide maximal inhibition of fibrinolysis but may be equally effective in decreasing transfusion of blood products. Effective lower dose regimens may decrease the incidence of seizures and possibly morbidity and mortality.

Summary

The lysine analogues are a key addition to blood conservation efforts in cardiac surgery. Finding an optimized dosing regimen is complex and may include factors such as total dosage and timing of administration. Understanding of the pharmacokinetics and pharmacodynamics of these drugs will help perioperative physicians evaluate their own practice and improve their own regimens.
Literatur
1.
Slaughter TF, Greenberg CS. Antifibrinolytic drugs and perioperative hemostasis. Am J Hematol. 1997;56(1):32–6.CrossRef
2.
• Tibi P, McClure RS, Huang J, Baker RA, Fitzgerald D, Mazer CD, et al. STS/SCA/AmSECT/SABM Update to the clinical practice guidelines on patient blood management. J Cardiothorac Vasc Anesth. 2021;35(9):2569–91. (This update to the 2011 STS and SCA clinical practice guidelines on blood management reports that the use of either EACA or TXA during cardiac surgery reduces blood loss and the need for transfusion and has an ACC/AHA recommendation level of 1A.)CrossRef
3.
Salenger R, Mazzeffi MA. The 7 pillars of blood conservation in cardiac surgery. Innovations. 2021;16(6):504–9.CrossRef
4.
Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319–31.CrossRef
5.
Bolliger D, Erb JM. Individualized perioperative antifibrinolytic therapy: the next goal in cardiac surgery? J Cardiothorac Vasc Anesth. 2021;35(2):418–20.CrossRef
6.
• Wu G, Quek AJ, Caradoc-Davies TT, Ekkel SM, Mazzitelli B, Whisstock JC, et al. Structural studies of plasmin inhibition. Biochem Soc Trans. 2019;47(2):541–57. (This article reviews the information related to plasminogen and plasmin from a biochemical perspective and provides useful information regarding the mechanism of action of lysine analogues.)CrossRef
7.
Chandler WL, Alessi MC, Aillaud MF, Vague P, Juhan-Vague I. Formation, inhibition and clearance of plasmin in vivo. Haemostasis. 2000;30(4):204–18.
8.
Bolliger D, Tanaka KA. Tranexamic acid in vascular surgery: antifibrinolytic or clot-stabilising activity. Br J Anaesth. 2020;124(1):4–6.CrossRef
9.
Eisses MJ, Seidel K, Aldea GS, Chandler WL. Reducing hemostatic activation during cardiopulmonary bypass: a combined approach. Anesth Analg. 2004;98(5):1208–16 (table of contents).CrossRef
10.
Butterworth J, James RL, Lin Y, Prielipp RC, Hudspeth AS. Pharmacokinetics of ε-aminocaproic acid in patients undergoing aortocoronary bypass surgery. Anesthesiology: J Am Soc Anesthesiol. 1999;90(6):1624–35.CrossRef
11.
Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology. 2002;97(2):390–9.CrossRef
12.
•• Strauss ER, Dahmane E, Judd M, Guo D, Williams B, Meyer M, et al. A Pharmacokinetic and pharmacodynamic investigation of an ε-aminocaproic acid regimen designed for cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2021;35(2):406–17. (This study reports pharmacokinetic (PK) and pharmacodynamic (PD) data for 21 patients undergoing cardiac surgery and receiving EACA at a single center. The EACA regimen would be considered low dose (15 g) but includes a bolus dose near end of cardiopulmonary bypass which was shown to coincide with peak fibrinolytic activity in this study. Blood conservation efforts that focused on minimizing hemodilution were used.)CrossRef
13.
•• Strauss ER, Li S, Henderson R, Carpenter R, Guo D, Thangaraju K, et al. A pharmacokinetic and plasmin-generation pharmacodynamic assessment of a tranexamic acid regimen designed for cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2022;36(8):2473–82. (This study reports the PK and PD for 20 patients receiving low total perioperative dose (2.5 g) TXA during cardiac surgery at a single center. The PD assessment includes an assay which provides a more accurate assessment of TXA effect on plasmin generation.)CrossRef
14.
Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys. 1952;40(2):346–51.CrossRef
15.
Andersson L, Nilsoon IM, Colleen S, Granstrand B, Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann N Y Acad Sci. 1968;146(2):642–58.CrossRef
16.
• Picetti R, Shakur-Still H, Medcalf RL, Standing JF, Roberts I. What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2019;30(1):1–10. (This study provides a systemic review of PD studies related to TXA for cardiac surgery and suggests that 10–15 mg/L provided substantial inhibition of fibrinolysis. This concentration is supported by in vitro studies. The authors support more in vivo studies.)CrossRef
17.
Nielsen VG, Cankovic L, Steenwyk BL. ε-Aminocaproic acid inhibition of fibrinolysis in vitro: should the ‘therapeutic’ concentration be reconsidered? Blood Coag Fibrinol. 2007;18(1):35–9.CrossRef
18.
Simpson ML, Goldenberg NA, Jacobson LJ, Bombardier CG, Hathaway WE, Manco-Johnson MJ. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults. Thromb Res. 2011;127(4):317–23.CrossRef
19.
Ilich A, Bokarev I, Key NS. Global assays of fibrinolysis. Int J Lab Hematol. 2017;39(5):441–7.CrossRef
20.
Miszta A, Huskens D, Donkervoort D, Roberts MJM, Wolberg AS, de Laat B. Assessing plasmin generation in health and disease. Int J Mol Sci. 2021;22(5):2758.CrossRef
21.
Miszta A, Ahmadzia HK, Luban NLC, Li S, Guo D, Holle LA, et al. Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery. J Thromb Haemost. 2021;19(1):221–32.CrossRef
22.
Tanaka KA, Henderson R, Thangaraju K, Morita Y, Mazzeffi MA, Strauss E, et al. In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients. Haemophilia. 2022;28(1):183–90.CrossRef
23.
Davies AJ, Strachan CJ, Hurlow RA, Stuart J. Fibrinolytic activity of tissue surfaces during surgery. J Clin Pathol. 1979;32(8):822–5.CrossRef
24.
Faraoni D, Levy JH. Optimal tranexamic acid dosing regimen in cardiac surgery: what are the missing pieces? Anesthesiology. 2021;134(2):143–6.CrossRef
25.
Olson JD, Cunningham MT, Higgins RA, Eby CS, Brandt JT. D-dimer: simple test, tough problems. Arch Pathol Lab Med. 2013;137(8):1030–8.CrossRef
26.
Moroz LA, Gilmore NJ. Fibrinolysis in normal plasma and blood: evidence for significant mechanisms independent of the plasminogen-plasmin system. Blood. 1976;48(4):531–45.CrossRef
27.
•• Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017;376(2):136–48. (An important large-scale study that involved more than 4000 patients and showed that TXA administration during cardiac surgery does not increase the risk of death or major thrombotic complications. As a secondary endpoint, TXA reduced blood production transfusion and re-operation for bleeding.)CrossRef
28.
Maeda T, Ishihara T, Miyata S, Yamashita K, Sasaki H, Kobayashi J, et al. Evaluating the effect on mortality of a no-tranexamic acid (TXA) policy for cardiovascular surgery. J Cardiothorac Vasc Anesth. 2018;32(4):1627–34.CrossRef
29.
Couture P, Lebon J-S, Laliberté É, Desjardins G, Chamberland M-È, Ayoub C, et al. Low-dose versus high-dose tranexamic acid reduces the risk of nonischemic seizures after cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2017;31(5):1611–7.CrossRef
30.
Lecker I, Wang DS, Romaschin AD, Peterson M, Mazer CD, Orser BA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest. 2012;122(12):4654–66.CrossRef
31.
Rabinovici R, Heyman A, Kluger Y, Shinar E. Convulsions induced by aminocaproic acid infusion. DICP. 1989;23(10):780–1.CrossRef
32.
Guthrie GD, Nicholson-Guthrie CS. gamma-Aminobutyric acid uptake by a bacterial system with neurotransmitter binding characteristics. Proc Natl Acad Sci U S A. 1989;86(19):7378–81.CrossRef
33.
Martin K, Knorr J, Breuer T, Gertler R, Macguill M, Lange R, et al. Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth. 2011;25(1):20–5.CrossRef
34.
Manji RA, Grocott HP, Leake J, Ariano RE, Manji JS, Menkis AH, et al. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anaesth. 2012;59(1):6–13.CrossRef
35.
• Hulde N, Zittermann A, Deutsch M-A, von Dossow V, Gummert JF, Koster A. Associations of preoperative stroke and tranexamic acid administration with convulsive seizures in valvular open-heart surgery. J Anesth. 2021;35(3):451–4. (This retrospective study analyzed 16,110 cardiac surgery patients. Results show TXA and a preoperative history of stroke are both independent risk factors for seizure post cardiac surgery and there is no significant interaction between preoperative stroke and TXA on the risk of seizures. In-hospital mortality and 30-day mortality risk was higher in patient who had post-operative seizures.)CrossRef
36.
Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, et al. Anti‐fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011;2011(3):CD001886.
37.
Slaughter TF, Faghih F, Greenberg CS, Leslie JB, Sladen RN. The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg. 1997;85(6):1221–6.CrossRef
38.
Vander Salm TJ, Ansell JE, Okike ON, Marsicano TH, Lew R, Stephenson WP, et al. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J Thorac Cardiovasc Surg. 1988;95(3):538–40.CrossRef
39.
Troianos CA, Sypula RW, Lucas DM, D’Amico F, Mathie TB, Desai M, et al. The effect of prophylactic epsilon-aminocaproic acid on bleeding, transfusions, platelet function, and fibrinolysis during coronary artery bypass grafting. Anesthesiology. 1999;91(2):430–5.CrossRef
40.
Kikura M, Levy JH, Tanaka KA, Ramsay JG. A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg. 2006;202(2):216–22; quiz A44–5.
41.
Greilich PE, Jessen ME, Satyanarayana N, Whitten CW, Nuttall GA, Beckham JM, et al. The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial. Anesth Analg. 2009;109(1):15–24.CrossRef
42.
•• Zufferey PJ, Lanoiselée J, Graouch B, Vieille B, Delavenne X, Ollier E. Exposure–response relationship of tranexamic acid in cardiac surgery: a model-based meta-analysis. Anesthesiology. 2021;134(2):165–78. (A meta-analysis that shows a mild dose-dependent effect of TXA on bleeding and transfusion. The dose-related effect on the incidence of seizures was stronger and showed that compared to no TXA, a low-dose TXA regimen (≈ 20 mg/kg) had a 1.2 relative risk and high dose (>80 mg/kg) had a 2.0 relative risk. The analysis was also used to model the weight of TXA level over time and shows that TXA level around the time of CPB end contributes the most to reduction in post-operative blood loss.)CrossRef
43.
Ray MJ, Hales MM, Brown L, O’Brien MF, Stafford EG. Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit. Ann Thorac Surg. 2001;72(2):521–6.CrossRef
44.
Samson AL, Alwis I, Maclean JAA, Priyananda P, Hawkett B, Schoenwaelder SM, et al. Endogenous fibrinolysis facilitates clot retraction in vivo. Blood. 2017;130(23):2453–62.CrossRef
Metadaten
Titel
Antifibrinolytics in Cardiac Surgery: What Is the Best Practice in 2022?
verfasst von
Erik R. Strauss
Monica Taneja
Richard Booth
Susan Sankova
Megan G. Anders
Publikationsdatum
13.10.2022
Verlag
Springer US
Erschienen in
Current Anesthesiology Reports / Ausgabe 4/2022
Elektronische ISSN: 2167-6275
DOI
https://doi.org/10.1007/s40140-022-00538-w

Weitere Artikel der Ausgabe 4/2022

Management of Neuromuscular Block in Pediatric Patients — Safety Implications

  • Patient Safety in Anesthesia (SJ Brull and JR Renew, Section Editors)

Preparing the Patient for ICU Transfer: What Is the Anesthesiologist’s Role?

  • Open Access
  • Patient Safety in Anesthesia (SJ Brull and JR Renew, Section Editors)

Intraoperative Monitoring During Neurosurgical Procedures and Patient Outcomes

  • Patient Safety in Anesthesia (SJ Brull and JR Renew, Section Editors)

Impact of Closed-Loop Technology, Machine Learning, and Artificial Intelligence on Patient Safety and the Future of Anesthesia

  • Patient Safety in Anesthesia (SJ Brull and JR Renew, Section Editors)

Patient Safety in Anesthesia: Hand Hygiene and Perioperative Infection Control

  • Patient Safety in Anesthesia (SJ Brull and JR Renew, Section Editors)

Pediatric Neuroanesthesia — a Review of the Recent Literature

  • Open Access
  • Patient Safety in Anesthesia (SJ Brull and JR Renew, Section Editors)

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Neu im Fachgebiet AINS

Antibiotika bei Bakteriämie – 7 versus 14 Tage

  • 21.01.2025
  • Sepsis
  • Nachrichten

Eine Bakteriämie lässt sich mit einer einwöchigen Antibiotikatherapie zumeist gut in den Griff bekommen: Die Sterberate ist nicht höher als unter zweiwöchiger Behandlung, zeigt eine Vergleichsstudie mit hospitalisierten Erkrankten. Allerdings muss die Therapie bei fast jedem Vierten verlängert werden.

Nasenstimulation lindert chronische Migräne

Wird die Naseninnenseite durch Vibrationen stimuliert, kann dies offenbar die Zahl der Migränetage von Menschen mit chronischer Migräne deutlich senken. Darauf deuten die Resultate einer randomisiert-kontrollierten deutsch-finnischen Untersuchung.

Nackenschmerzen nach Bandscheibenvorfall: Muskeltraining hilft!

Bei hartnäckigen Schmerzen aufgrund einer zervikalen Radikulopathie schlägt ein Team der Universität Istanbul vor, lokale Steroidinjektionen mit einem speziellen Trainingsprogramm zur Stabilisierung der Nackenmuskulatur zu kombinieren.

Okzipitale Nervenstimulation: Op.-Erfahrungen aus Dänemark

Derzeit gibt es kein breit akzeptiertes Standardprotokoll, was das chirurgische Vorgehen bei okzipitaler Nervenstimulation betrifft. Ein Ärzteteam aus Dänemark hat nun seinen Ansatz vorgestellt, der bestimmte Vorteile bieten soll.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise